# Novel AAT Administration Methods Research

**Document Version**: 1.0
**Last Updated**: November 8, 2025
**Owner**: Chief Medical Officer
**Purpose**: Define research strategy for developing alternative delivery methods for Alpha-1 Antitrypsin augmentation therapyâ€”replacing inconvenient weekly IV infusions with patient-friendly options

---

## ðŸ“‹ Table of Contents

1. [Research Overview](#research-overview)
2. [Current IV Therapy Limitations](#current-iv-therapy-limitations)
3. [Novel Delivery Approaches](#novel-delivery-approaches)
4. [Subcutaneous Administration](#subcutaneous-administration)
5. [Inhaled AAT Therapy](#inhaled-aat-therapy)
6. [Sustained-Release Formulations](#sustained-release-formulations)
7. [Research Partnerships](#research-partnerships)
8. [Clinical Development Strategy](#clinical-development-strategy)
9. [Timeline & Investment](#timeline--investment)
10. [Patient Impact Modeling](#patient-impact-modeling)

---

## Research Overview

### The Problem: IV Infusions Are Burdensome

**Current Standard of Care**:

- Weekly IV infusions (60 mg/kgâ€”typically 1-2 hours per infusion)
- Requires vascular access (IV catheter insertion weeklyâ€”painful, risk of infection)
- Location-dependent (infusion center, home health nurse, or self-infusionâ€”scheduling burden)
- Weekly disruption (miss work, childcare coordination, travel logistics)

**Patient Burden**:

- **52 infusions/year** (every week for lifeâ€”no breaks)
- **52-104 hours/year** in infusion chair (1-2 hours Ã— 52 weeks)
- **Cost**: $100K-$200K/year (insurance coverage requiredâ€”financial stress)
- **Compliance challenges**: 20-30% miss infusions (travel, illness, insurance gapsâ€”leads to disease progression)

**The Vision**: Convenient, patient-friendly delivery options

- âœ… Self-administered at home (no nurse, no infusion centerâ€”patient independence)
- âœ… Less frequent dosing (every 2 weeks? monthly? sustained-release?)
- âœ… Reduced time burden (5 minutes vs. 2 hoursâ€”patient gets life back)
- âœ… Lower cost (simpler delivery = lower healthcare costsâ€”better insurance coverage)

---

## Current IV Therapy Limitations

### Why IV Is Current Standard

**Pharmacokinetics**:

- AAT is large protein (52 kDaâ€”394 amino acids)
- Must reach bloodstream (circulate to lungsâ€”protect against neutrophil elastase)
- IV delivery = 100% bioavailability (all infused AAT reaches circulation)

**Dosing**:

- 60 mg/kg weekly (typical patient: 70 kg Ã— 60 mg/kg = 4,200 mg = 4.2 grams AAT/week)
- Target trough level: >57 mg/dL (protective thresholdâ€”prevents emphysema progression)

**FDA Approval**:

- 4 brands approved (Prolastin-C, Aralast, Zemaira, Glassiaâ€”all IV only)
- Proven effective (slows emphysema 30-40%, reduces exacerbations, mortality benefit)

---

### Patient Burden Quantified

**Survey Data** (Alpha-1 Foundation patient survey, N=1,200):

- **78% report infusions disrupt life** (work, family, social activities)
- **43% delayed/skipped infusions** (due to travel, illness, insurance issues)
- **65% would prefer alternative** (subcutaneous, inhaled, less frequentâ€”if equally effective)
- **31% considered stopping therapy** (due to burdenâ€”even though life-saving)

**Economic Burden**:

- Lost productivity: 52 hours/year Ã— $30/hour = $1,560/patient/year (time off work)
- Caregiver burden: 20% need assistance (family member takes time offâ€”additional $500-$1,000/year lost wages)
- Travel costs: $10-$50/infusion (for patients without home healthâ€”$520-$2,600/year)

**Clinical Impact of Non-Compliance**:

- Missing >25% of infusions (13+ per year) associated with:
  - 2x faster lung function decline (FEV1 loss)
  - 3x more hospitalizations (COPD exacerbations)
  - Lower quality of life (dyspnea, activity limitation)

---

## Novel Delivery Approaches

### Three Promising Strategies

**1. Subcutaneous (Under-Skin) Injection**:

- Patient self-injects (like insulinâ€”small needle, fatty tissue under skin)
- Frequency: 2-3x per week (vs. 1x IVâ€”but easier, faster)
- Location: Abdomen, thigh (rotate sitesâ€”minimize discomfort)

**2. Inhaled AAT Therapy**:

- Nebulizer or dry powder inhaler (breathe in AATâ€”directly to lungs)
- Daily dosing (vs. weekly IVâ€”but self-administered, 5-10 minutes)
- Direct lung delivery (high local concentrationâ€”lower systemic dose needed?)

**3. Sustained-Release Formulations**:

- Long-acting AAT (modified protein, nanoparticle encapsulationâ€”slower release)
- Frequency: Every 2-4 weeks (vs. weeklyâ€”fewer interventions)
- Delivery: IV or subcutaneous (depends on formulation)

---

## Subcutaneous Administration

### Rationale: Proven in Other Diseases

**Precedent**:

- **Immunoglobulins** (IVIG â†’ SubQ IGâ€”now standard for primary immunodeficiency)
- **Biologics** (TNF inhibitors, IL-17 inhibitorsâ€”rheumatoid arthritis, psoriasisâ€”almost all SubQ now)
- **Insulin** (diabetics self-inject SubQ dailyâ€”decades of safety data)

**Why It Could Work for AAT**:

- Large protein (but immunoglobulins are largerâ€”150 kDa vs. 52 kDa AATâ€”SubQ works for them)
- Absorption: Lymphatic uptake (SubQ proteins drain into lymph â†’ bloodstreamâ€”slower absorption, sustained levels)
- Bioavailability: 60-80% (vs. 100% IVâ€”need higher dose to compensate, but still less than 2x)

---

### Research Approach: Pharmacokinetic Studies

**Phase 1: Dose-Finding (Years 1-2)**

**Study Design**:

- **N**: 20 healthy volunteers (no AATDâ€”establish safety, PK)
- **Dose**: 60 mg/kg SubQ (split into 2-3 injectionsâ€”max 2 mL per site)
- **Frequency**: Compare weekly vs. 2x/week vs. 3x/week
- **Endpoints**:
  - Plasma AAT levels (measure daily Ã— 1 weekâ€”see absorption curve, trough levels)
  - Safety (injection site reactions, systemic side effects)
  - Bioavailability (AUC SubQ vs. AUC IVâ€”calculate % absorbed)

**Expected Outcomes**:

- Bioavailability: 60-80% (based on immunoglobulin data)
- Trough levels: >57 mg/dL achievable with 2-3x/week dosing (higher frequency compensates for lower bioavailability)
- Safety: Mild injection site reactions (redness, swellingâ€”resolves in 1-2 days)

**Budget**: $2M (clinical trial, AAT product, lab assays)

---

**Phase 2: Proof-of-Concept in AATD Patients (Years 3-4)**

**Study Design**:

- **N**: 50 AATD patients (ZZ or SZâ€”currently on IV therapy)
- **Dose**: 80-100 mg/kg/week SubQ (split into 3 injectionsâ€”compensate for lower bioavailability)
- **Duration**: 6 months
- **Endpoints**:
  - Primary: Trough AAT levels >57 mg/dL (protective threshold)
  - Secondary: Lung function (FEV1â€”stable?), quality of life (SGRQâ€”improve?), patient preference (prefer SubQ vs. IV?)

**Expected Outcomes**:

- Trough levels achieved in 80-90% of patients (some may need dose adjustment)
- FEV1 stable (non-inferior to IVâ€”no loss of efficacy)
- Quality of life improves (less time burden, more independenceâ€”higher SGRQ scores)
- 70-80% prefer SubQ (despite more frequent injectionsâ€”convenience outweighs frequency)

**Budget**: $5M

---

**Phase 3: Pivotal Trial (Years 5-7)**

**Study Design**:

- **N**: 300 patients (randomizedâ€”SubQ vs. IV)
- **Duration**: 2 years
- **Primary Endpoint**: Lung function (FEV1 declineâ€”SubQ non-inferior to IV)
- **Secondary**: Exacerbations, QOL, safety, cost-effectiveness

**Success Criteria**: SubQ non-inferior to IV (FDA approval pathwayâ€”new delivery route for existing drug)

**Budget**: $30M (likely pharma-funded at this stage)

---

### Challenges & Solutions

**Challenge 1: Injection Volume**

- **Problem**: 4-5 grams AAT = 40-50 mL volume (too large for single SubQ injectionâ€”max 2 mL per site)
- **Solution**: Split into 3 injections (15-20 mL eachâ€”abdomen, both thighs), or
- **Solution**: Concentrate formulation (e.g., 200 mg/mL vs. 50 mg/mLâ€”reduce volume 4x, but viscosity increases)

**Challenge 2: Absorption Variability**

- **Problem**: SubQ absorption varies by injection site, patient body composition (fat vs. muscleâ€”affects uptake)
- **Solution**: Standardize injection technique (training program), rotate sites consistently, monitor trough levels (adjust dose if needed)

**Challenge 3: Injection Frequency**

- **Problem**: 3x/week SubQ (more frequent than 1x/week IVâ€”may seem worse)
- **Solution**: Emphasize convenience (3 injections at home = 15 min/week vs. 1 infusion at clinic = 2+ hoursâ€”net time savings), patient preference data (most prefer SubQ despite frequency)

---

## Inhaled AAT Therapy

### Rationale: Direct Lung Delivery

**Why Inhaled Makes Sense**:

- AATD damages lungs (not other organsâ€”neutrophil elastase destroys alveoli in lower lobes)
- IV therapy raises systemic AAT (circulates everywhereâ€”only small fraction reaches lung tissue)
- Inhaled delivers AAT directly to alveoli (high local concentrationâ€”may be more effective, need lower total dose)

**Precedent**:

- Inhaled antibiotics (cystic fibrosisâ€”tobramycin, aztreonam inhaled vs. IVâ€”equally effective, fewer side effects)
- Inhaled steroids (asthmaâ€”budesonide, fluticasoneâ€”standard of care, topical lung delivery minimizes systemic effects)

---

### Research Approach: Formulation Development

**Phase 1: Aerosolized AAT Stability (Years 1-2)**

**Challenges**:

- AAT is large protein (may not aerosolize wellâ€”requires small particles <5 microns to reach alveoli)
- Shear stress (nebulization can denature proteinâ€”lose activity)
- Lung deposition (only 10-20% of inhaled drug reaches targetâ€”rest deposited in mouth, throat, swallowed)

**Formulation Options**:

**1. Nebulized Solution**:

- Dissolve AAT in saline (100-200 mg/mL)
- Nebulize (jet nebulizer or mesh nebulizerâ€”generate aerosol)
- Inhale over 10-20 minutes
- Pros: Simple, proven for other proteins (DNase in CF)
- Cons: Time-consuming (20 min daily), equipment needed, protein stability concerns

**2. Dry Powder Inhaler (DPI)**:

- Lyophilize AAT (freeze-dry into powder)
- Mix with excipients (lactose, mannitolâ€”improve aerosolization)
- Inhale (patient breathes in forcefullyâ€”powder disperses into fine particles)
- Pros: Fast (1-2 minutes), portable, no equipment
- Cons: Requires strong inhalation (may be difficult for severe COPD patientsâ€”weak inspiratory flow)

**Research**:

- Test formulations (nebulized vs. DPIâ€”which maintains AAT activity? achieves lung deposition?)
- Animal studies (administer to mice, ratsâ€”measure AAT in lung tissue, plasma)
- Healthy volunteer PK study (20 subjectsâ€”inhale AAT, measure lung deposition by scintigraphy, plasma levels)

**Budget**: $3M

---

**Phase 2: Proof-of-Concept (Years 3-4)**

**Study Design**:

- **N**: 40 AATD patients (mild-moderate COPDâ€”FEV1 40-80% predicted)
- **Dose**: 100-500 mg inhaled AAT daily (dose-findingâ€”determine minimum effective dose)
- **Duration**: 3 months
- **Endpoints**:
  - AAT in sputum (measureâ€”does it increase? reach therapeutic levels?)
  - Neutrophil elastase activity (sputum assayâ€”decrease = AAT is working)
  - Lung function (FEV1â€”stable? improve?)
  - Systemic AAT levels (does any reach bloodstream? likely minimalâ€”mostly local)

**Expected Outcomes**:

- Sputum AAT increases 10-100x (dose-dependent)
- Neutrophil elastase activity decreases 50-80% (AAT inhibits enzyme locally)
- FEV1 stable or slight improvement (particularly in patients with frequent exacerbationsâ€”inhaled AAT may reduce inflammation)
- Systemic AAT remains low (<20 mg/dLâ€”confirming local delivery, not systemic)

**Budget**: $5M

---

**Phase 3: Efficacy Trial (Years 5-8)**

**Study Design**:

- **N**: 200 patients (randomizedâ€”inhaled AAT vs. placebo, or inhaled + IV vs. IV alone)
- **Duration**: 2 years
- **Primary Endpoint**: Lung function decline (FEV1 ml/yearâ€”does inhaled AAT slow progression?)
- **Secondary**: Exacerbations, CT densitometry (emphysema progression), QOL

**Success Scenario**: Inhaled AAT slows FEV1 decline (non-inferior to IV, or synergistic with IVâ€”combination better than either alone)

**Budget**: $30M-$50M

---

### Challenges & Solutions

**Challenge 1: Lung Deposition Efficiency**

- **Problem**: Only 10-20% of inhaled dose reaches lungs (rest wastedâ€”expensive protein lost)
- **Solution**: Optimize device (mesh nebulizer, breath-actuated inhalerâ€”improve efficiency), tolerate lower efficiency (if clinical benefit demonstrated, cost may be acceptable)

**Challenge 2: Systemic vs. Local Protection**

- **Problem**: Inhaled AAT may not raise plasma levels (IV still needed for systemic protectionâ€”upper lobes, liver?)
- **Solution**: Position as adjunct therapy (inhaled + IVâ€”combination may allow lower IV dose, fewer infusions), or target mild disease (inhaled monotherapy for early-stage AATDâ€”delay need for IV)

**Challenge 3: Daily Dosing**

- **Problem**: Daily inhalation (vs. weekly IVâ€”may seem more burdensome)
- **Solution**: Fast delivery (DPI = 2 min/day vs. IV = 2 hours/weekâ€”net time savings), home convenience (no travel to infusion center)

---

## Sustained-Release Formulations

### Rationale: Reduce Dosing Frequency

**Why Sustained-Release?**

- AAT has short half-life (4-5 daysâ€”weekly dosing maintains trough >57 mg/dL, but levels fluctuate)
- Goal: Extend half-life to 14-30 days (bi-weekly or monthly dosingâ€”fewer interventions)

**Approaches**:

**1. PEGylation** (Attach Polyethylene Glycol to AAT):

- PEG chains shield protein (reduce kidney clearanceâ€”extend half-life 2-5x)
- Precedent: PEGylated interferon (hepatitis Câ€”weekly vs. daily), PEGylated EPO (anemiaâ€”monthly vs. weekly)
- Pros: Proven technology, relatively simple
- Cons: PEG may reduce AAT activity (steric hindranceâ€”less binding to neutrophil elastase), immunogenicity concerns (anti-PEG antibodies)

**2. Fc Fusion** (Fuse AAT to Antibody Fragment):

- Link AAT to Fc region of IgG (recycles through FcRn receptorâ€”extends half-life 3-10x)
- Precedent: Fc-fusion proteins (etanercept, romiplostimâ€”weekly/monthly dosing)
- Pros: Extends half-life dramatically, no activity loss
- Cons: Expensive to manufacture (recombinant protein production), immunogenicity (novel fusion proteinâ€”may trigger immune response)

**3. Nanoparticle Encapsulation**:

- Encapsulate AAT in biodegradable nanoparticles (PLGAâ€”poly(lactic-co-glycolic acid))
- Particles slowly degrade (release AAT over 1-4 weeksâ€”sustained plasma levels)
- Precedent: Long-acting antipsychotics (Risperdal Constaâ€”monthly injection), contraceptives (Depo-Proveraâ€”3-month injection)
- Pros: Flexible release kinetics (tune particle size, polymer compositionâ€”control release rate)
- Cons: Complex manufacturing, stability concerns (protein may denature during encapsulation)

---

### Research Strategy: Protein Engineering

**Phase 1: Lead Selection (Years 1-3)**

**Approach**:

- Engineer 5-10 AAT variants (PEGylated, Fc-fusion, nanoparticle formulationsâ€”different designs)
- Test in vitro:
  - Activity (neutrophil elastase inhibitionâ€”maintain >80% of native AAT activity?)
  - Stability (protein integrity after modificationâ€”no aggregation, denaturation)
- Test in mice:
  - Pharmacokinetics (single doseâ€”measure plasma AAT over 2-4 weeks, calculate half-life)
  - Efficacy (elastase-induced emphysema modelâ€”does long-acting AAT protect lungs?)

**Selection Criteria**:

- Half-life >14 days (enable bi-weekly or monthly dosing)
- Activity >80% of native AAT (ensure therapeutic efficacy)
- No immunogenicity (no anti-AAT antibodies in mice)

**Budget**: $5M

---

**Phase 2: First-in-Human (Years 4-5)**

**Study Design**:

- **N**: 30 AATD patients
- **Dose**: Escalating (start low, increase if safeâ€”establish maximum tolerated dose)
- **Dosing Interval**: Every 2 weeks (vs. weekly IVâ€”test if trough maintained)
- **Duration**: 3 months
- **Endpoints**:
  - Pharmacokinetics (plasma AAT levelsâ€”achieve trough >57 mg/dL?)
  - Safety (adverse events, immunogenicityâ€”anti-drug antibodies)
  - Activity (maintain neutrophil elastase inhibition?)

**Budget**: $10M

---

**Phase 3: Pivotal Trial (Years 6-9)**

**Study Design**:

- **N**: 300 patients (randomizedâ€”long-acting AAT vs. standard IV)
- **Duration**: 2 years
- **Endpoints**: FEV1 decline (non-inferiority), patient preference, cost-effectiveness

**Success**: FDA approval for monthly AAT therapy (game-changerâ€”12 doses/year vs. 52)

**Budget**: $50M-$100M (pharma partnership required)

---

## Research Partnerships

### Academic Partners

**Target Institutions**:

- **University of Florida** (Mark Brantly, MDâ€”AATD clinical research)
- **UC San Diego** (Joe Ramsdell, MDâ€”inhaled protein therapy expert)
- **Duke University** (protein engineering coreâ€”Fc-fusion, PEGylation expertise)

**Collaboration**:

- Foundation funds formulation development (grants $500K-$2M/project)
- Academics conduct research (preclinical studies, early clinical trials)
- Foundation co-owns IP (negotiate licenses to pharmaâ€”royalty revenue)

---

### Pharmaceutical Partners

**Target Companies**:

- **CSL Behring** (makes Zemairaâ€”largest AAT manufacturer, interested in next-gen formulations)
- **Grifols** (makes Prolastin-Câ€”also interested in improving delivery)
- **Takeda** (makes Glassiaâ€”Japanese market, global reach)
- **Kamada** (Glassiaâ€”smaller company, may be more flexible partner)

**Partnership Models**:

1. **Co-Development**: Foundation discovers formulation â†’ partner manufactures, runs trials, commercializes
2. **Licensing**: Foundation licenses IP â†’ partner pays royalties (5-10% of sales)
3. **Sponsored Research**: Partner funds Foundation research (in exchange for exclusive license option)

---

### Device Partners (For Inhaled Therapy)

**Target Companies**:

- **PARI Pharma** (nebulizer manufacturerâ€”eFlow mesh nebulizer, used for inhaled antibiotics in CF)
- **Vectura** (dry powder inhaler technologyâ€”acquired by Philip Morris, but DPI expertise remains)
- **Insmed** (inhaled protein therapyâ€”ARIKAYCE for MAC lung disease, relevant experience)

**Collaboration**:

- Partner provides device/formulation expertise (optimize AAT for inhalation)
- Foundation funds clinical trials (proof-of-concept, efficacy studies)
- Revenue share (if product commercializedâ€”device + AAT combination)

---

## Clinical Development Strategy

### Parallel Development Tracks

**Track 1: Subcutaneous (Fastest to Market)**

- Timeline: 7-10 years
- Advantage: Proven approach (SubQ immunoglobulins already approvedâ€”regulatory path clear)
- Investment: $40M-$60M (moderateâ€”pharma likely to fund Phase 3)

**Track 2: Inhaled (Higher Risk, High Reward)**

- Timeline: 10-15 years
- Advantage: Novel mechanism (direct lung deliveryâ€”may be superior to IV)
- Investment: $50M-$100M (highâ€”requires more preclinical work, proof-of-concept)

**Track 3: Sustained-Release (Long-Term)**

- Timeline: 10-15 years
- Advantage: Transformative (monthly dosingâ€”massive QOL improvement)
- Investment: $100M-$200M (very highâ€”protein engineering, complex development)

**Foundation Strategy**: Fund early-stage research for all 3 tracks (Years 1-5, $10M-$20M), partner with pharma for late-stage (Phase 3, FDA approvalâ€”pharma invests $50M-$200M)

---

## Timeline & Investment

### Years 1-5: Foundation-Funded Research

**Activities**:

- Subcutaneous PK studies (Phase 1/2â€”healthy volunteers, AATD patients)
- Inhaled formulation development (nebulized, DPIâ€”stability, lung deposition)
- Sustained-release engineering (PEGylation, Fc-fusion, nanoparticlesâ€”lead selection)

**Milestones**:

- âœ… Year 2: Subcutaneous Phase 1 complete (bioavailability demonstrated)
- âœ… Year 3: Inhaled proof-of-concept (sputum AAT increased, elastase inhibited)
- âœ… Year 4: Sustained-release lead selected (half-life >14 days, activity maintained)
- âœ… Year 5: Pharma partnerships secured (license agreements signedâ€”late-stage funding committed)

**Budget**: $15M

---

### Years 6-10: Pharma-Funded Development

**Activities**:

- Subcutaneous Phase 3 trial (300 patientsâ€”non-inferiority to IV)
- Inhaled Phase 2/3 trials (efficacy, dose-finding)
- Sustained-release Phase 1/2 (first-in-human, dose escalation)

**Milestones**:

- âœ… Year 7: Subcutaneous FDA approval (first alternative to IVâ€”commercially available)
- âœ… Year 9: Inhaled Phase 3 enrollment complete
- âœ… Year 10: Sustained-release Phase 2 data (bi-weekly dosing feasible)

**Budget**: $100M-$200M (pharma-fundedâ€”Foundation receives royalties)

---

### Years 10+: Market Transformation

**Outcomes**:

- Subcutaneous AAT: 30-50% of patients switch (prefer convenienceâ€”even if more frequent)
- Inhaled AAT: 10-20% use as adjunct (combination with IV or SubQâ€”reduce systemic dose)
- Sustained-release AAT: 50-70% switch (once availableâ€”monthly dosing preferred by most)

**Patient Impact**:

- 20,000-30,000 patients benefit (improved QOL, better complianceâ€”slower disease progression)
- $50M-$100M/year healthcare savings (reduced infusion center costs, fewer missed doses = fewer exacerbations)

---

## Patient Impact Modeling

### Scenario 1: Subcutaneous Adoption (Conservative)

**Assumptions**:

- Subcutaneous approved Year 7
- 30% of IV patients switch (9,000 of 30,000 US patients on augmentation)
- Compliance improves 20% (fewer missed dosesâ€”SubQ more convenient)

**Clinical Impact**:

- FEV1 decline: 30 mL/year slower (due to better complianceâ€”protective AAT levels maintained)
- Exacerbations: 15% reduction (2.0 â†’ 1.7 per yearâ€”fewer hospitalizations)
- Quality of life: SGRQ improves 5 points (time savings, independenceâ€”clinically meaningful)

**Economic Impact**:

- Healthcare savings: $30M/year (fewer exacerbations = $10K saved per patient per year)
- Patient savings: $4M/year (time, travel costsâ€”$500 per patient per year)

---

### Scenario 2: Inhaled + IV Combination (Optimistic)

**Assumptions**:

- Inhaled approved Year 10 (as adjunct to IV)
- 20% of IV patients add inhaled (6,000 patientsâ€”particularly those with frequent exacerbations)
- Synergistic benefit (local + systemic AATâ€”superior to either alone)

**Clinical Impact**:

- FEV1 decline: 50 mL/year slower (combination therapyâ€”enhanced lung protection)
- Exacerbations: 30% reduction (2.0 â†’ 1.4 per yearâ€”inhaled AAT reduces local inflammation)

**Economic Impact**:

- Cost: $30K/year additional (inhaled AATâ€”on top of $150K IV therapy)
- Savings: $12K/year (fewer exacerbationsâ€”30% Ã— $40K hospitalization cost)
- Net: Cost-neutral or slight savings (higher drug cost offset by fewer hospitalizations)

---

### Scenario 3: Monthly Sustained-Release (Transformative)

**Assumptions**:

- Monthly AAT approved Year 12
- 70% of patients switch (21,000 patientsâ€”most prefer less frequent dosing)
- Compliance improves 50% (monthly dosing easier to remember, less burdenâ€”near-perfect adherence)

**Clinical Impact**:

- FEV1 decline: 50 mL/year slower (perfect complianceâ€”trough levels always maintained)
- Exacerbations: 40% reduction (2.0 â†’ 1.2 per yearâ€”consistent AAT levels, no troughs)
- Quality of life: SGRQ improves 10 points (life-changingâ€”12 doses/year vs. 52)

**Economic Impact**:

- Drug cost: Similar to IV (manufacturing economies of scaleâ€”offset by less frequent administration)
- Healthcare savings: $80M/year (fewer exacerbations, better outcomesâ€”reduced hospitalizations, ER visits)
- Patient savings: $20M/year (time, travelâ€”massive time savings, productivity gains)

---

## Success Metrics

### Research Outputs (Years 1-5)

**Publications**:

- 5-10 peer-reviewed papers (AJRCCM, Thorax, Journal of Controlled Releaseâ€”establish scientific credibility)

**Patents**:

- 3-5 patent filings (SubQ formulation, inhaled device/formulation, sustained-release AAT variants)

**Partnerships**:

- 2-3 pharma collaborations (CSL, Grifols, Takedaâ€”license agreements signed)

---

### Clinical Milestones (Years 5-10)

**FDA Approvals**:

- Year 7: Subcutaneous AAT (first alternative deliveryâ€”commercially available)
- Year 10: Inhaled AAT (pendingâ€”Phase 3 ongoing)

**Patient Enrollment**:

- 500+ patients in Foundation-sponsored trials (generate real-world data, build clinical evidence)

---

### Patient Impact (Years 10-20)

**Adoption**:

- 50-70% of augmentation patients use alternative delivery (SubQ, inhaled, or sustained-releaseâ€”IV becomes niche)

**Outcomes**:

- Compliance improves 30-50% (fewer missed dosesâ€”alternative methods more convenient)
- Disease progression slows 20-30% (better compliance â†’ sustained AAT levels â†’ slower emphysema)
- Quality of life improves (patient independence, time savingsâ€”meaningful impact on daily life)

---

### Revenue to Foundation (Years 7-20)

**Licensing Deals**:

- Upfront + milestones: $20M-$50M (SubQ, inhaled, sustained-releaseâ€”combined)

**Royalties**:

- Annual revenue: $10M-$30M/year (assuming $1B-$3B annual sales of alternative formulations, 1-3% royaltyâ€”funds Foundation programs in perpetuity)

---

## Summary

**Alternative AAT Delivery = Transforming Patient Lives**:

- âœ… **Subcutaneous**: Self-inject at home (convenience, independenceâ€”no more infusion centers)
- âœ… **Inhaled**: Direct to lungs (high local concentrationâ€”potentially more effective, adjunct to IV)
- âœ… **Sustained-Release**: Monthly dosing (12 doses/year vs. 52â€”life-changing reduction in burden)

**10-Year Vision**: From research â†’ FDA approval â†’ market transformation (majority of patients use patient-friendly delivery)

**"Why should patients spend their lives in infusion chairs when we can bring therapy home?"**

---

**Support Novel Delivery Research**

**Mark Egly Foundation Research Lab**
ðŸ“§ Email: research@markeglyfoundation.org
ðŸ’Š Clinical Trials: trials@markeglyfoundation.org
ðŸ’° Donate to Research: MarkEglyFoundation.org/Research

---

**Approved by**: Board of Directors
**Effective Date**: January 1, 2026
**Review Date**: Annually
**Version**: 1.0

---

_"Therapy should fit into patients' lives, not the other way around."_

**â€” Mark Egly Foundation**
